Incomplete immunological recovery following anti-tuberculosis treatment in HIV-infected individuals with active tuberculosis

Indian Journal of Medical Research

Volumn 129, Issue 5, 2009, Pages 548-554

  Hanna, L E ^a   Nayak, Kaustuv ^a   Subramanyam, Sudha ^a   Venkatesan, Perumal ^a   Narayanan, P R ^a   Swaminathan, Soumya ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

Author keywords

Anti tuberculosis treatment; HIV 1; Immune activation; Mycobacterium tuberculosis; Neopterin; STNF RI 2 microglobulin

Indexed keywords

BETA 2 MICROGLOBULIN; ETHAMBUTOL; ISONIAZID; NEOPTERIN; PYRAZINAMIDE; RIFAMPICIN; SOLUBLE TUMOR NECROSIS FACTOR ALPHA RECEPTOR TYPE 1; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PROTEIN BLOOD LEVEL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANALYSIS OF VARIANCE; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CELL COUNT; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHAMBUTOL; HUMANS; INDIA; ISONIAZID; NEOPTERIN; PYRAZINAMIDE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RIFAMPIN; TUBERCULOSIS;

EID: 70349139710     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Swaminathan S, Ramachandran R, Baskaran G, Paramasivan CN, Ramanathan U, Venkatesan P, et al. Risk of development of tuberculosis in HIV-infected patients. Int J Tuberc Lung Dis 2000; 4: 839-44.
2. NIH News. 1996. USA. Available at: http://www3.niaid.nih.gov/news/ newsreleases/1996/tbhiv.htm; accessed on June 9, 2008.
3. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996; 157: 1271-8.
4. Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001; 14: 753-77.
5. Chaisson RE, Gallant JE, Keruly JC, Moore RD. Impact of opportunistic diseases on survival in patients with HIV infection. AIDS 1998; 12: 29-33.
6. Villacian JS, Tan GB, Teo LF, Paton NI. The effect of infection with Mycobacterium tuberculosis on T-cell activation and proliferation in patients with and without HIV co-infection. J Infect 2005; 51: 408-12.
7. Fahey JL, Taylor JM, Manna B, Nishanian P, Aziz N, Giorgi J, et al. Prognostic signifi cance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS 1998; 12: 1518-90.
8. Lawn SD, Rudolph D, Wiktor S, Coulibaly D, Ackah A, Lal RB. Tuberculosis (TB) and HIV infection are independently associated with elevated serum concentrations of tumour necrosis factor receptor type 1 and beta 2-microglobulin, respectively. Clin Exp Immunol 2000; 122: 79-84.
9. Phillips AN, Sabin CA, Elford J, Bofi ll M, Timms A, Janossy G, et al. Serum β2-microglobulin at HIV-1 seroconversion as a predictor of severe immunodeficiency during 10 years of follow up. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13: 262-6.
10. Stein DS, Lyles RH, Graham NM, Tassoni CJ, Margolick JB, Phair JP, et al. Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and beta 2-microglobulin. Multicenter AIDS Cohort Study. J Infect Dis 1997; 176: 1161-7.
11. Fahey JL. Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodefi ciency virus infection. Clin Diagn Lab Immunol 1998; 5: 597-603.
12. Fahey JL, Prince H, Weaver M, Groopman J, Visscher B, Schwartz K, et al. Qualitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders. Am J Med 1984; 76: 95-100.
13. Wallis RS, Helfand MS, Whalen CC, Johnson JL, Mugerwa RD, Vjecha M, et al. Immune activation, allergic drug toxicity and mortality in HIV-positive tuberculosis. Tuber Lung Dis 1996; 77: 516-23.
14. Vanham G, Edmonds K, Qing L, Hom D, Toossi Z, Jones B, et al. Generalized immune activation in pulmonary tuberculosis: coactivation with HIV infection. Clin Exp Immunol 1996; 103: 30-4.
15. Hertoghe T, Wajja A, Ntambi L, Okwera A, Aziz MA, Hirsch C, et al. T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB). Clin Exp Immunol 2000; 122: 350-7.
16. Law KF, Jagirdar J, Weiden MD, Bodkin M, Rom WN. Tuberculosis in HIV-positive patients: cellular response and immune activation in the lung. Am J Respir Crit Care Med 1996; 153: 1377-84.
17. Melmed RN, Taylor JM, Detels R, Bozorgmehri M, Fahey JL. Serum neopterin changes in HIV-infected subjects: indicator of signifi cant pathology, CD4 T cell changes, and the development of AIDS. J Acquir Immune Defififi c Syndr 1989; 2: 70-6.
18. Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, et al. The prognostic value of cellular and serologic markers in infection with human immunodefi ciency virus type 1. N Engl J Med 1990; 322: 166-72.
19. Verhofstede C, Reniers S, Van Wanzeele F, Plum J. Evaluation of proviral copy number and plasma RNA level as early indicators of progression in HIV-1 infection: correlation with virological and immunological markers of disease. AIDS 1994; 8: 1421-7.
20. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 1988; 9: 150-5.
21. Wirleitner B, Schroecksnadel K, Winkler C, Fuchs D. Neopterin in HIV-1 infection. Mol Immunol 2005, 42: 183-94.
22. Baier-Bitterlich G, Wachter H, Fuchs D. Role of neopterin and 7,8-dihydroneopterin in human immunodeficiency virus infection: marker for disease progression and pathogenic link. J Acquir Immune Defififi c Syndr Hum Retrovirol 1996; 13: 184-93.
23. Lacey JN, Forbes MA, Waugh MA, Cooper EH, Hambling MN. Serum beta-2-microglobulin and human immunodeficiency virus infection. AIDS 1987; 1: 123-7.
24. Lifson AR, Hessol NA, Buchbinder SP, O'Malley PM, Barnhart L, Segal M, et al. Serum beta 2-microglobulin and prediction of progression to AIDS in HIV infection. Lancet 1992; 339: 1436-40.
25. Godfried MH, van der Poll T, Weverling GJ, Mulder JW, Jansen J, van Deventer SJ, et al. Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodefi ciency virus type 1 infection. J Infect Dis 1994; 169: 739-45.
26. Kiepiela P, Smith AN, Rosenberg E. Laboratory markers associated with progression of HIV infection. Best Pract Res Clin Obstet Gynaecol 2005; 19: 243-54.
27. Plaeger S, Bass HZ, Nishanian P, Thomas J, Aziz N, Detels R, et al. The prognostic signifi cance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes. Clin Immunol 1999; 90: 238-46.
28. Subramanyam S, Hanna LE, Venkatesan P, Sankaran K, Narayanan PR, Swaminathan S. HIV alters plasma and M. tuberculosis-induced cytokine production in patients with tuberculosis. J Interferon Cytokine Res 2004; 24: 101-6.
29. Aziz N, Nishanian P, Mitsuyasu R, Detels R, Fahey JL. Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol 1999; 6: 89-95.
30. Immanuel C, Victor L, Chelvi KS, Padmapriyadarsini C, Rehman F, Iliayas S, et al. Serum neopterin levels in HIV infected patients with & without tuberculosis. Indian J Med Res 2005; 121: 220-5.
31. Moss AR, Bacchetti P, Osmond D, Krampf W, Chaisson RE, Stites D, et al. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J (Clin Res Ed) 1998; 296: 745-50.
32. Kalou M, Sassan-Morokro M, Abouya L, Bile C, Maurice C, Maran M, et al. Changes in HIV RNA viral load, CD4+ T-cell count, and levels of immune activation markers associated with anti-tuberculosis therapy and cotrimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Cote d'Ivoire. J Med Virol 2005; 75: 202-8.